← Eichor
Study identifier: NCT05535361 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

Condition: Short Bowel Syndrome  ·  Sponsor: Eclipse Regenesis, Inc.

PhaseNA
Planned participants40
Who can joinAll sexes, 3 Months to 65 Years
Healthy volunteersNo

About this study

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome

This description comes directly from the study's public registry record.

Talk to the study team

Andre Bessette  ·  (617)249-0955  ·  andre@eclipseregenesis.com

Eric Bannon  ·  (781)710-8243  ·  ebannon@alvamed.com

Always discuss trial participation with your own doctor first.

Locations (6)

Lucile Packard Children's Hospital StanfordPalo Alto, California, United StatesRecruiting
University of California San FranciscoSan Francisco, California, United StatesRecruiting
Stanford University School of MedicineStanford, California, United StatesRecruiting
Children's National HospitalWashington D.C., District of Columbia, United StatesRecruiting
Boston Children's HospitalBoston, Massachusetts, United StatesRecruiting
Cincinnati Children's HospitalCincinnati, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05535361